SUMMARY Diuretic therapy is frequently accompanied by undesirable biochemical changes and side-effects. Two multicenter trials compared the effects of captopril combined with a diuretic to the administration of either agent alone in mild-to-moderate hypertensives. In addition to blood pressure, effects on serum potassium, uric acid, glucose, and cholesterol were examined. The first study (Study A) was conducted on 210 such patients randomly assigned to receive: 1) hydrochlorothiazide (H) 15 mg three times daily (t.i. In Study A, the combination of C + H (A-3) produced a significantly greater (p < 0.001) reduction in blood pressure than either agent alone. In Study B, both C + H groups (B-l, B-2) had a significantly greater (p < 0.01) blood pressure reduction than that seen with C alone (B-3).
M
ORE than 25 years have elapsed since the availability of therapy for hypertension. Diuretics were among the first antihypertensive agents, followed by a number of increasingly specialized and effective agents. Since the advent of antihypertensive therapy, several studies have been conducted demonstrating the beneficial effect of blood pressure reduction on cardiovascular morbidity and mortality. Recent studies have been interpreted by some investigators as suggesting that certain antihypertensive drugs, particularly those of the diuretic class, may adversely affect cardiovascular risk. As a result, a closer look is being taken at the metabolic effects of diuretics.
Among the most frequently encountered side-effects of diuretics are: hypokalemia, hyperuricemia, and increased blood glucose and lipid levels. Asymptomatic hypokalemia may be a greater risk factor for sudden death than has previously been recognized 1 " 3 and invariably occurs when proximal tubule or loop diuretics are used. 4 Diuretic-induced increases in uric acid may precipitate gout in rare patients or predispose them to urolithiasis. In addition, uric acid has been shown to be a risk factor for coronary artery disease. 5 Diuretics may raise blood sugar, worsening the control of diabetes mellitus or precipitating its manifestations. 6 More recently, it has been shown that diuretic therapy of hypertension may raise serum lipid levels. 7 The latter by guest on June 14, 2017
http://hyper.ahajournals.org/ Downloaded from observation has been invoked to explain the failure of some therapeutic trials in hypertension to demonstrate a reduction in coronary artery disease rates. A more recent study from Sweden 8 suggests that the diuretic effect on triglycerides may be restricted to a subset of hypertensives also demonstrating a rise in uric acid levels. Thus, multiple, additive effects may occur in some diuretic-treated patients.
These and numerous other studies, as well as clinical experience, have renewed concern about the impact of diuretic-induced metabolic changes on hypertensive patients. We report the effect of administration of an angiotensin converting-enzyme inhibitor, captopril (C), alone or in combination with the diuretic hydrochlorothiazide (H) on these factors in two studies of mild-to-moderate essential hypertensives.
Methods
Both studies to be described were performed at multiple sites (see Acknowledgments). All studies were approved by the appropriate institutional review board, and informed consent was obtained from each subject after explanation of the studies to be performed. Excluded from the study were women with childbearing potential, and patients with secondary forms of hypertension, a recent history of myocardial infarction or cerebral vascular accident, significant renal dysfunction (creatinine clearance <50 ml/min; serum creatinine >2.0 mg/dl or urinary protein excretion >0.5 g/24 hrs), systemic lupus erythematosis, or significant hepatic dysfunction. All antihypertensive drugs were withdrawn 2 weeks before entry into the placebo phase of the study. Supine diastolic blood pressure was between 92 and 109 mm Hg. In Study A, 255 patients fulfilling all study criteria were randomly assigned to one of three treatment groups at the end of the placebo period; Group A-l received H 15 mg t.i.d., Group A-2 received C 25 mg t.i.d.; and Group A-3 received both drugs (C + H) in the same doses. In Study B, 535 patients entered a 4-week placebo period, after which 415 qualified subjects were randomly assigned to one of five treatment groups: All patients were seen every 2 weeks for 6 weeks. They were examined between 3 and 8 hours after the last drug dose. Physical examinations, chest x-rays, and ECGs were performed in the placebo period as well as laboratory studies, including a complete blood count, urinalysis, quantitative 24-hour urinary protein excretion, and routine blood chemistries. The laboratory studies were performed at the end of the placebo and active treatment periods. Patients were discontinued from the study due to any severe adverse reaction, an absolute neuterophil count of <1000 mm 3 , at the request of the patient, or the judgment of the investigator.
Data were analyzed in comparison to baseline (last placebo visit) using linear statistical models and Duncan's multiple range tests. Chi-square analyses were also used, and statistical significance was determined by Bonferroni critical values. Mean arterial pressure was calculated as diastolic pressure plus 'A (systolicdiastolic). In addition, the effect on supine diastolic blood pressure was also evaluated by classifying observations as: normalization (<90 mm Hg and > 5 % decrease from placebo), response (>90 mm Hg and > 10% decrease from baseline); and nonresponse (>90 mm Hg and <10% decrease from baseline).
Results
For Study A 9 and as shown in table 1 for Study B, the demographic characteristics of patients randomly assigned to the various treatment groups were not significantly different. As shown in figure 1 , the baseline supine blood pressure at the end of the 4-week placebo period also was not different for the five groups of patients in Study B. Figure 2 (Study A) and Figure 3 (Study B) depict the mean supine blood pressure in the placebo period and after varying periods of treatment, as indicated. In Study A, a significant (p < 0.05) decrease in blood pressure was seen in all three groups; the response in the group receiving both C and H was significantly (p < 0.05) greater than either monotherapy group. In the Study B ( fig. 3 ), a significant (p < 0.05) decrease in blood pressure was seen in all groups except those receiving placebo only (B-5). While the greatest decreases in blood pressures were seen in Groups B-1 and B-2 receiving both agents, the differences were not statistically significant when compared to the other groups receiving active drug. C25BID C50BID H25BID H25BID C50 BID PBID P BID H25BID PBID PBID
FIGURE 3. Study B. Changes in average systolic and diastolic blood pressures from placebo (P) (hatched) compared with 6 and 12 weeks (open bars) of active treatment with captopril (C) and hydrochlorothiazide (H). Significant (p < 0.001) decreases in blood pressure were observed in all groups but those receiving P only.
The proportion of patients whose blood pressure normalized or whose diastolic pressure decreased at least 10% from placebo with active treatment is tabulated for both studies (table 2) . In Study A, the responses of the combination group (C + H), in which 84% of the subjects responded significantly (p < 0.05), was greater than that of either monotherapy group. In Study B, all active treatment groups had a significantly (p < 0.01) greater response rate than those receiving only placebo, where one-fourth of the population had a significant decrease in blood pressure. Again, the combination therapy groups had the greatest responses (74% to 77%). With captopril monotherapy (B-3), 52% of the subjects responded.
The changes in serum potassium are shown in figure  4 (Study A) and figure 5 (Study B). A significant (p < 0.05) decrease in serum potassium concentration was observed in every group receiving H (A-l, A-3, B-l, B-2, and B-4). No changes in serum potassium were seen in the groups receiving C alone (A-2, B-3 < 10% decrease) C = captopril; H = hydrochlorothiazide; P = placebo.
•Different from other active treatment groups (p < 0.05). tDifferent from all other groups (p < 0.01).
placebo alone (B-5). The combination of C and H was associated with a lesser decrease in serum potassium levels than observed with H alone. A-3, B-2), inhibition of the H-induced hyperglycemia was observed, but not at doses of 50 mg/day (B-1).
The changes in serum uric acid are shown in figures 6 (Study A) and 7 (Study B). Uric acid levels increased in all groups receiving H (A-l, A-3, B-l, B-2 and B-4). No change was seen in the groups receiving C (A-2, B-3) or placebo (B-5) alone. The addition of C to H in Study

001) increases were seen in all groups receiving hydrochlorothiazide (H) compared to captopril (C) and placebo (P).
In Study A serum cholesterol also increased significantly (p < 0.05) with H treatment alone ( fig. 9 ), but failed to increase significantly with C alone (A-2) or in combination with the H (A-3) . In the Study B (table 3) , a significant (p < 0.05) rise in serum cholesterol was observed with H alone (B-4) and when H was combined with 50 mg/day of C (B-1). With C alone (B-3), a slight but insignificant fall in cholesterol was found and no change was observed when 100 mg C was combined with H.
The side-effects observed in these studies are listed in table 4. The most frequent complaint was of dizziness, which occurred most often in patients receiving both drugs. Headaches were reported as often by patients receiving placebo only as those taking active medication. A skin rash was more likely to occur in patients receiving C than in the other groups. 
Discussion
These studies confirm many previous reports demonstrating the antihypertensive efficacy of C alone or with a diuretic in mild-to-moderate essential hypertensives. In addition, Study B demonstrates that C 100 mg/day is as effective as H 50 mg/day, and both studies clearly demonstrate the additive effect of combining the two agents on blood pressure. In all combination therapy groups of both studies, beneficial blood pressure responses were seen in 77% to 84% of the patients, a response rate unequaled by any monotherapy group. In Study 2, there were no differences in the response rate with C 100 mg/day (B-2) when compared to C 50 mg/day (B-l) combined with H. These observations support the role of C as a second-step drug when a diuretic a|one does not control blood pressure or is contraindicated in the treatment of mild-to-moderate essential hypertension.
As previously mentioned, diuretic therapy has received considerable scrutiny because of its potentially harmful metabolic side-effects. Despite the short duration of the studies (6 weeks) and the modest doses of H (45-50 mg/day), significant (p < 0.05) alterations in serum potassium, uric acid, glucose, and cholesterol were seen in the groups receiving H monotherapy in both studies. The magnitude of the decrease in serum potassium levels seen in both studies (0.5-0.6 mEq/ liter) is consistent with other reports using similar doses of intermediate-acting diuretics and less than results observed with H 100 mg/day. The antihypertensive effect of H appears to be flat at doses greater than 50 mg/day. Thus, the increased potassium loss seen with higher doses seems difficult to justify in most patients. The risk of mild, asymptomatic hypokalemia in precipitating sudden death and cardiac arrhythmias has been the subject of considerable recent and renewed interest. Other studies, utilizing much higher doses of C than those used in the present studies, have reported the potassium-raising effect of angiotensin converting-enzyme inhibition. However, there have been few reports of the ability of lower doses of C (50-100 mg/day) to attenuate diuretic-induced hypokalemia besides the present studies. 910 Holland et al." have reported the antihypertensive efficacy of adding C in doses of 450 mg/day to diuretics in low renin essential hypertensives. At the larger doses used in that study, the authors reported a decreased need for potassium supplementation and a decreased incidence of diuretic-induced hyperglycemia.
No previous studies have reported the striking effect of these doses of C administration in the attenuation or prevention of three other diuretic-induced metabolic changes: hyperuricemia, hyperglycemia, and hypercholesterolemia. These diuretic side-effects have also received closer attention because of their identification as risk factors for vascular disease. The Framingham study 12 and the MRFTT study 13 have both emphasized the synergy between multiple cardiovascular disease risk factors. While elevated blood pressure heads the list, other factors are known to potentiate the risk of vascular disease. Thus, it is fitting that questions be raised about the slight, albeit significant, increases in these risk factors induced by diuretic therapy when extended over many years. While some investigators have suggested that diuretics should not be used as initial therapy in essential hypertensives, this would appear to be a rash recommendation in view of the multiple studies using diuretics as the initial antihypertensive agent which have provided the documentation that blood pressure reduction lowers cardiovascular morbidity and mortality. In an American population of essential hypertensives, only a miniscule proportion have a relative or absolute contraindication to the use of diuretics as initial therapeutic agents. In mild-tomoderate hypertensives who do not demonstrate adequate blood pressure control with diuretics alone, C can be expected to control blood pressure in over 75% when added to djuretic therapy based on the results of the present studies. Furthermore, the benefit of attenuating the diuretic-induced loss of potassium and increases in uric acid in addition to preventing the significant increases in glucose and cholesterol may have a beneficial effect on cardiovascular risk. Other "Step 2 " agents such as beta-blockers have been shown to raise serum potassium slightly, but they also raise glucose and cholesterol levels. Finally, at the doses of captopril employed in the present studies, the side effects observed were less frequent and/or less severe than those reported with higher doses in earlier studies, providing a safety profile comparable or better than current "Step 2 " agents.
